Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK: IMSA101, PULSAR, and Nivolumab in Metastatic Kidney Cancer
NCT06601296Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IMSA101 in renal cell carcinoma (RCC), sponsored by UT Southwestern Medical Center. Started Apr 2025; status: recruiting.
02
Drugs
IMSA101
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06601296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601296.